Advertisement
Original Article| Volume 258, P101-109, November 2021

Genotype-cancer association in patients with Fanconi anemia due to pathogenic variants in FANCD1 (BRCA2) or FANCN (PALB2)

      Highlights

      • There is a unique genotype-cancer association in FANCD1 and FANCN Fanconi anemia.
      • FANCN and FANCD1 Fanconi anemia patients often develop embryonic tumors early in life.
      • Mouse embryonic stem cell-based functional testing improves FANCD1 variant curation.

      Abstract

      Fanconi anemia (FA) is the most common inherited bone marrow failure syndrome and a cancer predisposition disorder. Cancers in FA include acute leukemia and solid tumors; the most frequent solid tumor is head and neck squamous cell carcinoma. FA is a primarily autosomal recessive disorder. Several of the genes in which biallelic pathogenic variants cause FA are also autosomal monoallelic cancer predisposition genes e.g. FANCD1 (BRCA2) and FANCN (PALB2). We observed that patients with FA due to biallelic or homozygous pathogenic variants in FANCD1 and FANCN have a unique cancer association. We curated published cases plus our NCI cohort cases, including 71 patients in the FANCD1 group (94 cancers and 69 variants) and 16 patients in the FANCN group (23 cancers and 20 variants). Only patients in FANCD1 and FANCN groups had one or more of these tumors: brain tumors (primarily medulloblastoma), Wilms tumor and neuroblastoma; this is a genotype-specific cancer combination of tumors of embryonal origin. Acute leukemias, seen in all FA genotypes, also occurred in FANCD1 and FANCN group patients at young ages. In silico predictions of pathogenicity for FANCD1 variants were compared with results from a mouse embryonic stem cell-based functional assay. Patients with two null FANCD1 variants did not have an increased frequency of cancer nor earlier onset of cancer compared with those with hypomorphic variants. Patients with FA and these specific cancers should consider genetic testing focused on FANCD1 and FANCN, and patients with these genotypes may consider ongoing surveillance for these specific cancers.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Taylor A.M.R.
        • Rothblum-Oviatt C.
        • Ellis N.A.
        • Hickson I.D.
        • Meyer S.
        • Crawford T.O.
        • Smogorzewska A.
        • Pietrucha B.
        • Weemaes C.
        • Stewart G.S.
        Chromosome instability syndromes.
        Nat Rev Dis Prim. 2019; 5: 64
        • Alter B.P.
        • Giri N.
        • Savage S.A.
        • Rosenberg P.S.
        Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up.
        Haematologica. 2018; 103: 30-39
        • Wegman-Ostrosky T.
        • Savage S.A.
        The genomics of inherited bone marrow failure: from mechanism to the clinic.
        Br J Haematol. 2017; 177: 526-542
        • Alter B.P.
        • Best A.F.
        Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
        Breast Cancer Res Treat. 2020; 182: 465-476
        • Alter B.P.
        • Rosenberg P.S.
        • Brody L.C.
        Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2.
        J Med Genet. 2007; 44: 1-9
        • Biswas K.
        • Das R.
        • Alter B.P.
        • Kuznetsov S.G.
        • Stauffer S.
        • North S.L.
        • Burkett S.
        • Brody L.C.
        • Meyer S.
        • Byrd R.A.
        • Sharan S.K.
        A comprehensive functional characterization of BRCA2 variants associated with Fanconi anemia using mouse ES cell-based assay.
        Blood. 2011; 118: 2430-2442
        • Biswas K.
        • Das R.
        • Eggington J.M.
        • Qiao H.
        • North S.L.
        • Stauffer S.
        • Burkett S.S.
        • Martin B.K.
        • Southon E.
        • Sizemore S.C.
        • Pruss D.
        • Bowles K.R.
        • Roa B.B.
        • Hunter N.
        • Tessarollo L.
        • Wenstrup R.J.
        • Byrd R.A.
        • Sharan S.K.
        Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.
        Hum Mol Genet. 2012; 21: 3993-4006
        • Biswas K.
        • Lipton G.B.
        • Stauffer S.
        • Sullivan T.
        • Cleveland L.
        • Southon E.
        • Reid S.
        • Magidsson V.
        • Iversen E.I.
        • Sharan S.K.
        A computational model for classification of BRCA2 variants using mouse embryonic stem cell-based functional assays.
        NJP Genom Med. 2020; 5: 52
        • Wang K.
        • Li M.
        • Hakonarson H.
        ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data.
        Nucleic Acids Res. 2010; 38: e164
        • Ioannidis N.M.
        • Rothstein J.H.
        • Pejaver V.
        • Middha S.
        • McDonnell S.K.
        • Baheti S.
        • Musolf A.
        • Li Q.
        • Holzinger E.
        • Karyadi D.
        • Cannon-Albright L.A.
        • Teerlink C.C.
        • Stanford J.L.
        • Isaacs W.B.
        • Xu J.
        • Cooney K.A.
        • Lange E.M.
        • Schleutker J.
        • Carpten J.D.
        • Powell I.J.
        • Cussenot O.
        • Cancel-Tassin G.
        • Giles G.G.
        • MacInnis R.J.
        • Maier C.
        • Hsieh C.L.
        • Wiklund F.
        • Catalona W.J.
        • Foulkes W.D.
        • Mandal D.
        • Eeles R.A.
        • Kote-Jarai Z.
        • Bustamante C.D.
        • Schaid D.J.
        • Hastie T.
        • Ostrander E.A.
        • Bailey-Wilson J.E.
        • Radivojac P.
        • Thibodeau S.N.
        • Whittemore A.S.
        • Sieh W.
        REVEL: an ensemble method for predicting the pathogenicity of rare missense variants.
        Am J Hum Genet. 2016; 99: 877-885
        • Rentzsch P.
        • Witten D.
        • Cooper G.M.
        • Shendure J.
        • Kircher M.
        CADD: predicting the deleteriousness of variants throughout the human genome.
        Nucleic Acids Res. 2019; 47: D886-Dd94
        • Kim S.
        • Jhong J.H.
        • Lee J.
        • Koo J.Y.
        Meta-analytic support vector machine for integrating multiple omics data.
        BioData Min. 2017; 10: 2
        • Guidugli L.
        • Shimelis H.
        • Masica D.L.
        • Pankratz V.S.
        • Lipton G.B.
        • Singh N.
        • Hu C.
        • Monteiro A.N.A.
        • Lindor N.M.
        • Goldgar D.E.
        • Karchin R.
        • Iversen E.S.
        • Couch F.J.
        Assessment of the clinical relevance of BRCA2 missense variants by functional and computational approaches.
        Am J Hum Genet. 2018; 102: 233-248
        • Guidugli L.
        • Carreira A.
        • Caputo S.M.
        • Ehlen A.
        • Galli A.
        • Monteiro A.N.
        • Neuhausen S.L.
        • Hansen T.V.
        • Couch F.J.
        • Vreeswijk M.P.
        Functional assays for analysis of variants of uncertain significance in BRCA2.
        Hum Mutat. 2014; 35: 151-164
        • Reid S.
        • Schindler D.
        • Hanenberg H.
        • Barker K.
        • Hanks S.
        • Kalb R.
        • Neveling K.
        • Kelly P.
        • Seal S.
        • Freund M.
        • Wurm M.
        • Batish S.D.
        • Lach F.P.
        • Yetgin S.
        • Neitzel H.
        • Ariffin H.
        • Tischkowitz M.
        • Mathew C.G.
        • Auerbach A.D.
        • Rahman N.
        Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer.
        Nat Genet. 2007; 39: 162-164
        • Byrd P.J.
        • Stewart G.S.
        • Smith A.
        • Eaton C.
        • Taylor A.J.
        • Guy C.
        • Eringyte I.
        • Fooks P.
        • Last J.I.
        • Horsley R.
        • Oliver A.W.
        • Janic D.
        • Dokmanovic L.
        • Stankovic T.
        • Taylor A.M.
        A hypomorphic PALB2 allele gives rise to an unusual form of FA-N associated with lymphoid tumour development.
        PLoS Genet. 2016; 12e1005945
        • Ameziane N.
        • Errami A.
        • Léveillé F.
        • Fontaine C.
        • de Vries Y.
        • van Spaendonk R.M.
        • de Winter J.P.
        • Pals G.
        • Joenje H.
        Genetic subtyping of Fanconi anemia by comprehensive mutation screening.
        Hum Mutat. 2008; 29: 159-166
        • Chandrasekharappa S.C.
        • Chinn S.B.
        • Donovan F.X.
        • Chowdhury N.I.
        • Kamat A.
        • Adeyemo A.A.
        • Thomas J.W.
        • Vemulapalli M.
        • Hussey C.S.
        • Reid H.H.
        • Mullikin J.C.
        • Wei Q.
        • Sturgis E.M.
        Assessing the spectrum of germline variation in Fanconi anemia genes among patients with head and neck carcinoma before age 50.
        Cancer. 2017; 123: 3943-3954
        • Johnson-Tesch B.A.
        • Gawande R.S.
        • Zhang L.
        • MacMillan M.L.
        • Nascene D.R.
        Fanconi anemia: correlating central nervous system malformations and genetic complementation groups.
        Pediatr Radiol. 2017; 47: 868-876
        • Alter B.P.
        • Rosenberg P.S.
        VACTERL-H association and Fanconi anemia.
        Mol Syndromol. 2013; 4: 87-93
        • Malric A.
        • Defachelles A.S.
        • Leblanc T.
        • Lescoeur B.
        • Lacour B.
        • Peuchmaur M.
        • Maurage C.A.
        • Pierron G.
        • Guillemot D.
        • d'Enghien C.D.
        • Soulier J.
        • Stoppa-Lyonnet D.
        • Bourdeaut F.
        Fanconi anemia and solid malignancies in childhood: a national retrospective study.
        Pediatr Blood Cancer. 2015; 62: 463-470
        • McReynolds L.J.
        • Wang Y.
        • Thompson A.S.
        • Ballew B.J.
        • Kim J.
        • Alter B.P.
        • Hicks B.
        • Zhu B.
        • Jones K.
        • Spellman S.R.
        • Wang T.
        • Lee S.J.
        • Savage S.A.
        • Gadalla S.M.
        Population frequency of Fanconi pathway gene variants and their association with survival after hematopoietic cell transplant for severe aplastic anemia.
        Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2020; 26: 817-822
        • Seo A.
        • Steinberg-Shemer O.
        • Unal S.
        • Casadei S.
        • Walsh T.
        • Gumruk F.
        • Shalev S.
        • Shimamura A.
        • Akarsu N.A.
        • Tamary H.
        • King M.C.
        Mechanism for survival of homozygous nonsense mutations in the tumor suppressor gene BRCA1.
        Proc Natl Acad Sci USA. 2018; 115: 5241-5246
        • Berrebi D.
        • Lebras M.N.
        • Belarbi N.
        • Couturier J.
        • Fattet S.
        • Faye A.
        • Peuchmaur M.
        • de Lagausie P
        Bilateral adrenal neuroblastoma and nephroblastoma occurring synchronously in a child with Fanconi's anemia and VACTERL syndrome.
        J Pediatr Surg. 2006; 41: e11-e14
        • Faivre L.
        • Portnoï M.F.
        • Pals G.
        • Stoppa-Lyonnet D.
        • Le Merrer M.
        • Thauvin-Robinet C.
        • Huet F.
        • Mathew C.G.
        • Joenje H.
        • Verloes A.
        • Baumann C
        Should chromosome breakage studies be performed in patients with VACTERL association?.
        Am J Med Genet Part A. 2005; 137: 55-58
        • Fiesco-Roa M.O.
        • Giri N.
        • McReynolds L.J.
        • Best A.F.
        • Alter B.P
        Genotype-phenotype associations in Fanconi anemia: a literature review.
        Blood Rev. 2019; 37100589
        • Jung M.
        • Ramanagoudr-Bhojappa R.
        • van Twest S.
        • Rosti R.O.
        • Murphy V.
        • Tan W.
        • Donovan F.X.
        • Lach F.P.
        • Kimble D.C.
        • Jiang C.S.
        • Vaughan R.
        • Mehta P.A.
        • Pierri F.
        • Dufour C.
        • Auerbach A.D.
        • Deans A.J.
        • Smogorzewska A.
        • Chandrasekharappa S.C.
        Association of clinical severity with FANCB variant type in Fanconi anemia.
        Blood. 2020; 135: 1588-1602
        • Xia B.
        • Dorsman J.C.
        • Ameziane N.
        • de Vries Y.
        • Rooimans M.A.
        • Sheng Q.
        • Pals G.
        • Errami A.
        • Gluckman E.
        • Llera J.
        • Wang W.
        • Livingston D.M.
        • Joenje H.
        • de Winter J.P.
        Fanconi anemia is associated with a defect in the BRCA2 partner PALB2.
        Nat Genet. 2007; 39: 159-161
        • Hanenberg H.
        • Andreassen P.R.
        PALB2 (partner and localizer of BRCA2).
        Atlas Genet Cytogenet Oncol Haematol. 2018; 22: 484-490
        • Bigley V.
        • Haniffa M.
        • Doulatov S.
        • Wang X.N.
        • Dickinson R.
        • McGovern N.
        • Jardine L.
        • Pagan S.
        • Dimmick I.
        • Chua I.
        • Wallis J.
        • Lordan J.
        • Morgan C.
        • Kumararatne D.S.
        • Doffinger R.
        • van der Burg M.
        • van Dongen J.
        • Cant A.
        • Dick J.E.
        • Hambleton S.
        • Collin M
        The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency.
        J Exp Med. 2011; 208: 227-234
      1. Webster A.L.H., Sanders M.A., Patel K., Dietrich R., Noonan R.J., Lach F.P., White R.R., Goldfarb A., Hadi K., Edwards M.M., Donovan F.X., Jung M., Sridhar S., Fedrigo O., Tian H., Rosiene J., Heineman T., Kennedy J.A., Bean L., Rosti O., Tryon R., Gonzalez A.-.M., Rosenberg A., Luo J.-.D., Carrol T., Velleuer E., Rastatter J.C., Wells S.I., Surrallés J., Bagby G., MacMillan M.L., Wagner J.E., Cancio M., Boulad F., Scognamiglio T., Vaughan R., Koren A., Imielinski M., Chandrasekharappa S., Auerbach A.D., Singh B., Kutler D.I., Campbell P.J., Smogorzewska A. Fanconi anemia pathway deficiency drives copy number variation in squamous cell carcinomas. bioRxiv 2021;preprint, 10.1101/2021.08.14.456365.

        • Ahmed A.A.
        • Mohamed A.D.
        • Gener M.
        • Li W.
        • Taboada E.
        YAP and the hippo pathway in pediatric cancer.
        Mol Cell Oncol. 2017; 4e1295127
        • Hamo S.
        • Bacchetta J.
        • Bertholet-Thomas A.
        • Ranchin B.
        • Cochat P.
        • Michel-Calemard L.
        [PKHD1 mutations in autosomal recessive polycystic kidney disease (ARPKD): genotype-phenotype correlations from a series of 308 cases to improve prenatal counselling].
        Nephrol Ther. 2018; 14: 474-477
        • Terlato N.J.
        • Cox G.F.
        Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature.
        Genet Med Off J Am Coll Med Genet. 2003; 5: 286-294
        • Carcao M.D.
        • van den Berg H.M.
        • Ljung R.
        • Mancuso M.E.
        Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A.
        Blood. 2013; 121 (s1): 3946-3952
        • Smith M.A.
        • Altekruse S.F.
        • Adamson P.C.
        • Reaman G.H.
        • Seibel N.L.
        Declining childhood and adolescent cancer mortality.
        Cancer. 2014; 120: 2497-2506
        • Meyer S.
        • Tischkowitz M.
        • Chandler K.
        • Gillespie A.
        • Birch J.M.
        • Evans D.G.
        Fanconi anaemia, BRCA2 mutations and childhood cancer: a developmental perspective from clinical and epidemiological observations with implications for genetic counselling.
        J Med Genet. 2014; 51: 71-75
        • Offit K.
        • Levran O.
        • Mullaney B.
        • Mah K.
        • Nafa K.
        • Batish S.D.
        • Diotti R.
        • Schneider H.
        • Deffenbaugh A.
        • Scholl T.
        • Proud V.K.
        • Robson M.
        • Norton L.
        • Ellis N.
        • Hanenberg H.
        • Auerbach A.D.
        Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia.
        J Natl Cancer Inst. 2003; 95: 1548-1551
        • Bayrakli F.
        • Akgun B.
        • Soylemez B.
        • Kaplan M.
        • Gurelik M.
        Variation in the BRCA2 gene in a child with medulloblastoma and a family history of breast cancer.
        J Neurosurg Pediatr. 2011; 8: 476-478
        • Reid S.
        • Renwick A.
        • Seal S.
        • Baskcomb L.
        • Barfoot R.
        • Jayatilake H.
        • Pritchard-Jones K.
        • Stratton M.R.
        • Ridolfi-Lüthy A.
        • Rahman N.
        Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour.
        J Med Genet. 2005; 42: 147-151
        • Steinberg-Shemer O.
        • Goldberg T.A.
        • Yacobovich J.
        • Levin C.
        • Koren A.
        • Revel-Vilk S.
        • Ben-Ami T.
        • Kuperman A.A.
        • Zemer V.S.
        • Toren A.
        • Kapelushnik J.
        • Ben-Barak A.
        • Miskin H.
        • Krasnov T.
        • Noy-Lotan S.
        • Dgany O.
        • Tamary H.
        Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population.
        Haematologica. 2020; 105: 1825-1834
        • Ikeda H.
        • Matsushita M.
        • Waisfisz Q.
        • Kinoshita A.
        • Oostra A.B.
        • Nieuwint A.W.
        • De Winter J.P.
        • Hoatlin M.E.
        • Kawai Y.
        • Sasaki M.S.
        • D'Andrea A.D.
        • Kawakami Y.
        • Joenje H
        Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2.
        Cancer Res. 2003; 63: 2688-2694
        • Bakker J.L.
        • Thirthagiri E.
        • van Mil S.E.
        • Adank M.A.
        • Ikeda H.
        • Verheul H.M.
        • Meijers-Heijboer H.
        • de Winter J.P.
        • Sharan S.K.
        • Waisfisz Q.
        A novel splice site mutation in the noncoding region of BRCA2: implications for Fanconi anemia and familial breast cancer diagnostics.
        Hum Mutat. 2014; 35: 442-446
      2. Fanconi Anemia Clinical Care Guidelines. Eugene, OR: Fanconi Anemia Research Fund, 2020.

        • Myers K.
        • Davies S.M.
        • Harris R.E.
        • Spunt S.L.
        • Smolarek T.
        • Zimmerman S.
        • McMasters R.
        • Wagner L.
        • Mueller R.
        • Auerbach A.D.
        • Mehta P.A.
        The clinical phenotype of children with Fanconi anemia caused by biallelic FANCD1/BRCA2 mutations.
        Pediatr Blood Cancer. 2012; 58: 462-465
        • Woods W.G.
        • Gao R.N.
        • Shuster J.J.
        • Robison L.L.
        • Bernstein M.
        • Weitzman S.
        • Bunin G.
        • Levy I.
        • Brossard J.
        • Dougherty G.
        • Tuchman M.
        • Lemieux B.
        Screening of infants and mortality due to neuroblastoma.
        N Engl J Med. 2002; 346: 1041-1046
        • Schilling F.H.
        • Spix C.
        • Berthold F.
        • Erttmann R.
        • Fehse N.
        • Hero B.
        • Klein G.
        • Sander J.
        • Schwarz K.
        • Treuner J.
        • Zorn U.
        • Michaelis J.
        Neuroblastoma screening at one year of age.
        N Engl J Med. 2002; 346: 1047-1053
        • Tischkowitz M.
        • Balmaña J.
        • Foulkes W.D.
        • James P.
        • Ngeow J.
        • Schmutzler R.
        • Voian N.
        • Wick M.J.
        • Stewart D.R.
        • Pal T.
        Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).
        Genet Med Off J Am Coll Med Genet. 2021; 23: 1416-1423
        • Degrolard-Courcet E.
        • Sokolowska J.
        • Padeano M.M.
        • Guiu S.
        • Bronner M.
        • Chery C.
        • Coron F.
        • Lepage C.
        • Chapusot C.
        • Loustalot C.
        • Jouve J.L.
        • Hatem C.
        • Ferrant E.
        • Martin L.
        • Coutant C.
        • Baurand A.
        • Couillault G.
        • Delignette A.
        • El Chehadeh S.
        • Lizard S.
        • Arnould L.
        • Fumoleau P.
        • Callier P.
        • Mugneret F.
        • Philippe C.
        • Frebourg T.
        • Jonveaux P.
        • Faivre L.
        Development of primary early-onset colorectal cancers due to biallelic mutations of the FANCD1/BRCA2 gene.
        Eur J Hum Genet EJHG. 2014; 22: 979-987
        • Ghazwani Y.
        • AlBalwi M.
        • Al-Abdulkareem I.
        • Al-Dress M.
        • Alharbi T.
        • Alsudairy R.
        • Alomari A.
        • Aljamaan K.
        • Essa M.
        • Al-Zahrani M.
        • Alsultan A
        Clinical characteristics and genetic subtypes of Fanconi anemia in Saudi patients.
        Cancer Genet. 2016; 209: 171-176
        • Sawyer S.L.
        • Tian L.
        • Kähkönen M.
        • Schwartzentruber J.
        • Kircher M.
        • Majewski J.
        • Dyment D.A.
        • Innes A.M.
        • Boycott K.M.
        • Moreau L.A.
        • Moilanen J.S.
        • Greenberg R.A.
        Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype.
        Cancer Discov. 2015; 5: 135-142
        • Wong-Brown M.
        • McPhillips M.
        • Gleeson M.
        • Spigelman A.D.
        • Meldrum C.J.
        • Dooley S.
        • Scott R.J.
        When is a mutation not a mutation: the case of the c.594-2A>C splice variant in a woman harbouring another BRCA1 mutation in trans.
        Hered Cancer Clin Pract. 2016; 14: 6
        • Bondavalli D.
        • Malvestiti F.
        • Pensotti V.
        • Feroce I.
        • Bonanni B.
        BRCA1 homozygous unclassified variant in a patient with non-Fanconi anemia: a case report.
        Oncol Lett. 2018; 15: 3329-3332
        • Keupp K.
        • Hampp S.
        • Hübbel A.
        • Maringa M.
        • Kostezka S.
        • Rhiem K.
        • Waha A.
        • Wappenschmidt B.
        • Pujol R.
        • Surrallés J.
        • Schmutzler R.K.
        • Wiesmüller L.
        • Hahnen E.
        Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility.
        Mol Genet Genom Med. 2019; 7: e863
        • Trejo Bittar H.E.
        • Radder J.E.
        • Ranganathan S.
        • Srinivasan A.
        • Madan-Khetarpal S.
        • Reyes-Múgica M
        Clear cell sarcoma of the kidney in a child with Fanconi anemia.
        Pediatr Dev Pathol Off J Soc Pediatr Pathol Paediatr Pathol Soc. 2014; 17: 297-301
        • Kopic S.
        • Eirich K.
        • Schuster B.
        • Hanenberg H.
        • Varon-Mateeva R.
        • Rittinger O.
        • Schimpl G.
        • Schindler D.
        • Jones N.
        Hepatoblastoma in a 4-year-old girl with Fanconi anaemia.
        Acta Paediatr. 2011; 100 (Oslo, Norway: 1992): 780-783
        • Mori M.
        • Hira A.
        • Yoshida K.
        • Muramatsu H.
        • Okuno Y.
        • Shiraishi Y.
        • Anmae M.
        • Yasuda J.
        • Tadaka S.
        • Kinoshita K.
        • Osumi T.
        • Noguchi Y.
        • Adachi S.
        • Kobayashi R.
        • Kawabata H.
        • Imai K.
        • Morio T.
        • Tamura K.
        • Takaori-Kondo A.
        • Yamamoto M.
        • Miyano S.
        • Kojima S.
        • Ito E.
        • Ogawa S.
        • Matsuo K.
        • Yabe H.
        • Yabe M.
        • Takata M.
        Pathogenic mutations identified by a multimodality approach in 117 Japanese Fanconi anemia patients.
        Haematologica. 2019; 104: 1962-1973
        • Domchek S.M.
        • Tang J.
        • Stopfer J.
        • Lilli D.R.
        • Hamel N.
        • Tischkowitz M.
        • Monteiro A.N.
        • Messick T.E.
        • Powers J.
        • Yonker A.
        • Couch F.J.
        • Goldgar D.E.
        • Davidson H.R.
        • Nathanson K.L.
        • Foulkes W.D.
        • Greenberg R.A.
        Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer.
        Cancer Discov. 2013; 3: 399-405